French drugmaker Sanofi has entered a collaboration and licence agreement with US-based Lexicon Pharmaceuticals to develop and commercialise sotagliflozin, which could be a potential treatment option for people with diabetes.Sotagliflozin is an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2).As part of the deal, Lexicon will receive an upfront payment of $300m and is eligible to receive development, regulatory and sales milestone payments of up to $1.4bn.In addition, Lexicon is entitled to tiered, escalating double digit percentage royalties of net sales of sotagliflozin.
Source: Sanofi and Lexicon to develop diabetes drug sotagliflozin – Pharmaceutical Technology
